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Conclusions: Serial respiration-correlated CT scans revealed important 
information on dosimetric consequences of anatomical changes during 
treatment. Preliminary data showed that variations in target and normal 
tissue volumes were small in average. Nevertheless, greater changes 
were observed in certain patients with larger tumor motion and in lower 
lobe lesions; therefore, effort to include image-guidance for setup and 
frequent imaging during the course of treatment, should be studied 
further.
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Purpose: It is challenging to integrate the emerging radiation technolo-
gy and evidences into daily practice. Physicians may differ in their treat-
ment decisions due to various considerations. The purpose of this study 
is to determine whether there is a signiﬁcant difference in practicing 
radiation therapy (RT) for non-small cell lung cancer (NSCLC) between 
radiation oncologists from the United States (US) and other countries. 
Methods: Study questionnaires were designed by a panel of 8 Ameri-
can Board certiﬁed radiation oncologists. The survey was sent through 
email to radiation oncologist members of American Society of Thera-
peutic Radiology and Oncology (ASTRO) on September 10th, 2006, 
with the results collected online on March 14th, 2007. There were a 
total of 796 responses; 705 of them were considered to be valid for this 
analysis. Chi-square tests were used to test for associations between 
country and practice patterns.
Results: The respondents saw an average of 8 new cases monthly 
(range 0-25). There were 425 responses from the US and 280 from 
other countries. There was no signiﬁcant difference in choices of radia-
tion regimen for stage I peripherally located disease: 34% vs 26%, 10% 
vs 15%, and 19% vs 24%, for conventional fractionated, hypofrac-
tioned, stereotactic RT and stereotactic radiation therapy, for US and 
non-US physicians, respectively. For stage I centrally located disease, 
the majority of respondents selected fractionated radiation therapy; 
there was no signiﬁcant difference between these two groups regarding 
the choices of fractionated (79% vs 73%) vs stereotactic RT (11% vs 
12%). The choices of fractionation scheme for stereotactic RT included 
18-20Gyx3, 15-17Gyx3, 8-11Gyx5, and 10Gyx6; more physicians 
were found to select 18-20Gyx3 from the US (14.3%) than from other 
countries (5.3%, p<0.001). For stage II and III, the dominant pattern of 
practice was concurrent chemoradiation; there were more respondents 
from the US (85%) that chose concurrent chemoradiation than from 
other countries (60% and 63% for stage II and III, p<0.001). Regarding 
choices of dose fractionation, the majority of respondents (91% vs 86% 
for US and non-US respectively) selected 60-70 Gy in 1.8-2 Gy daily 
fractions when radiation was combined with chemotherapy. More US 
respondents selected >70 Gy radiation (10% vs 3.6%, p=0.085). For 
stage IV disease, dose prescriptions ranged from from 0 Gy, 2.5Gyx20, 
3Gyx15, 3Gyx10, to 2Gyx30 in 25% vs 27%, 18% vs 5%, 7% vs 8%, 
13% vs 13%, and 27% vs 21% for US and non-US respondents, respec-
tively. There were signiﬁcantly more US respondents (P<0.001) that 
selected 50 Gy in 20 fractions. 
Conclusions: Although the dominant practice patterns are similar in 
many settings, more US physicians selected larger fraction size for ste-
reotactic RT, higher total dose for fractionated RT, and more concurrent 
chemoradiation for stage II/III NSCLC. The potential reasons for and 
societal impacts of these differences should be addressed.
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Background: It has been reported that plasma TGF-β1 at the end of 
radiation therapy (RT) in lung cancer was predictive of RILT. However, 
end of treatment evaluations cannot be used to adjust initial RT. The 
purpose of this international study was to investigate whether circulat-
ing TGF-β1during RT correlates with RILT so that remaining RT could 
be adapted according to the risk of toxicity.
Methods: Patients were from two institutions: University of Michigan 
Hospital (UM) and Cancer Hospital of Peking Union Medical Col-
lege and Chinese Academy of Medical Science (PUMC). Patients with 
stage I-III non-small cell lung cancer treated with fractionated RT were 
eligible for this study. Platelet poor plasma was obtained pre-RT and 
at 4 weeks (40-50 Gy) during-RT. TGF-β1 was measured using an 
enzyme-linked immunosorbent assay. The primary endpoint for RILT 
was ≥ grade 2 radiation pneumonitis or ﬁbrosis. Radiation-induced 
pulmonary function reduction was assessed by measuring forced vital 
capacity (FVC), forced expiratory volume in the ﬁrst second (FEV1), 
and diffusing capacity for carbon monoxide (DLCO) before RT and at 
three months after RT. Logistic regression and Chi-square were used 
for statistical analysis.
Results: Sixty-four patients with a minimum follow-up of 12 months 
were included. Twenty six were from UM and 38 were from PUMC. 
Fifty-seven were male and seven were female. The median age was 60 
years. Fifty received chemotherapy concurrently (54.7%) or sequen-
tially (23.4%) with RT. The median radiation dose was 63.9 Gy and the 
median mean lung dose (MLD) was 15.7 Gy. Three months after RT, 
DLCO declined to 54.8 ± 17.3% from a pre-RT level of 64.03 ± 17.9%, 
without a signiﬁcant reduction in FVC and FEV1. Eighteen patients 
(28.1%) experienced ≥ grade 2 RILT. No signiﬁcant difference in MLD 
was found between patients with RILT and those without RILT. When 
age, gender, disease stage, administration of chemotherapy, radia-
tion dose, MLD, pre-RT FVC, pre-RT FEV1, pre-RT DLCO, pre-RT 
TGF-β1, during-RT TGF-β, and TGF-β1 ratio (during-RT/pre-RT) 
were input into a logistic regression model, TGF-β1 ratio was the only 
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factor that signiﬁcantly correlated with the risk of RILT (P = 0.035, 
OR = 2.354). If patients were grouped based on high or low TGF-β1 
ratio (during RT/pre-RT), 13 out of the 29 patients with a TGF-β1 ratio 
higher than the median level of 0.8 developed RILT, while only 5 out 
of the 35 patients with low TGF-β1 ratios developed RILT (P = 0.007). 
No signiﬁcant correlation was seen between TGF-β1 ratio and MLD or 
between TGF-β1 ratio and the decline in DLCO
Conclusion: An increase in plasma TGF-β1 level during RT may be 
predictive of RILT. The potential use of TGF-β1 levels during RT to 
adapt RT delivery deserves further study.
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Objective: To study the relationship between level of plasma transform 
growth factor bata (TGF-beta), interleukin (IL-6), angiotensin-convert-
ing enzyme (ACE) and physical parameters (V10, V15, V20, MLD) 
and radiation pneumonitis (RP). 
Methods: The records of all patients with lung cancer treated with 
radiotherapy (RT) with curative intent from February 2004 to August 
2005. A total of 67 patients were identiﬁed who met the following 
inclusion criteria: (1) newly diagnosed lung cancer of any histology 
treated with RT± chemotherapy with curative intent; (2) a Karnofsky 
performance status >70; (3) expected survival >6 months; (4) follow-
up time more than 6 months; (5) no pneumonectomy. Blood samples 
were collected and measured with enzyme-linked immunosorbent assay 
(ELISA). TGF-beta, IL-6 and ACE measurements obtained before RT 
(Pre-RT) and when RT dose reached 40-50Gy (during-RT). Fifty-eight 
patients were treated with computed tomography based 3-dimensional 
planning and had dose-volume histogram data available. The endpoint 
of the study was the development of ≥ grade 2 RP (NCI [National Can-
cer Institute] common toxicity criteria 3.0). 
Results: The Median follow-up time of the alive patients is 22.6 
months. The incidence of ≥ grade 2 RP for all 67 patients was 25.4%. 
Between the RP and non-RP group, there was no difference in Pre- or 
during- RT level of TGF-beta, IL-6. We observed ACE level was lower 
in RP group than in the non-RP group, both pre-RT and during-RT 
(p=0.033 and p=0.004). Fifty-eight patients received 3-dimensional 
conformal RT (3DCRT). In RP group, patients are received higher all 
lung V10, contra lateral MLD, contra lateral V10, contra lateral V15, 
contra lateral V20 (44% vs 39%, 1931cGy vs 990cGy, 52% vs 35%, 
48% vs 27%, 37% vs 10% P< 0.05). The subgroup of 54 patients 
treated with 3DCRT and the data of ACE level were available, were 
divided into groups according to their plasma ACE median level and 
whether their V10 level was above or below the median of 40%; Group 
I (n=13), with ACE > 506ng/ml and V10 ≤ 40%; Group II (n=30), with 
ACE > 506ng/ml and V10 > 40%; ACE ≤ 506ng/ml and V10 ≤ 40%; 
Group III (n=12), with ACE ≤506ng/ml and V10 > 40%. A signiﬁcant 
different was found in the incidence of RP among these three groups 
(0%, 26.7%, 50.0% p=0.008) 
Conclusions: (1) A lower plasma ACE level during-RT is an indepen-
dent risk factor for RP; (2) The combination of plasma ACE level and 
V10 appears to facilitate stratiﬁcation of patients into three groups. 
Thus, combining both physical and biologic risk factors may allow for 
better identiﬁcation of patients at risk for the development of symptom-
atic radiation-induced lung pneumonitis.
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Background: Knowledge of changes in volume and motion of either 
tumor or involved lymph nodes during a course of radiotherapy is nec-
essary to improve the treatment (adaptive radiotherapy). These changes 
for the primary tumor were already reported (Bosmans et al, Int J 
Radiat Oncol Biol Phys, 2006). The purpose of this study is describing 
the time trends in nodal CT volume and nodal motion, for patients with 
locally advanced non-small cell lung cancer.
Methods: Eleven patients, with a total of 21 nodes, from a prospective 
clinical trial underwent CT-PET scans prior to treatment, which was 
repeated in the ﬁrst and second week following the start of radiothera-
py. For 20 nodes, the motion could be measured based on a respiration 
correlated CT (RCCT) scan. Moreover, repeated RCCT scans were 
available for 11 nodes to evaluate the change in motion. Patients were 
treated with an accelerated fractionation schedule, 1.8 Gy BID, with 
a total tumor dose depending on pre-set dose constraints for the lungs 
and the spinal cord. 
Results: A heterogeneity of nodal volume changes was observed at all 
time points similar to the tumor volume changes. In some patients the 
nodal volume increased > 50% (4/21) in others the volume decreased 
> 50% (1/21) but for the majority of nodal areas (16/21) the volume 
only changed slightly (< 50%). The initial absolute nodal volume was 
4.5 cc ± 4.3 cc, therefore large volume changes were observed and the 
delineation of small volumes is sensitive to intra-observer variability. 
On average the nodal volume did not change signiﬁcantly (4.5, 4.9 
and 4.3 cc prior to treatment, 1 and 2 weeks after the start of treatment 
respectively). The 3D vector motion, which is the quadratic sum of the 
